简体中文
繁體中文
English
Pусский
日本語
ภาษาไทย
Tiếng Việt
Bahasa Indonesia
Español
हिन्दी
Filippiiniläinen
Français
Deutsch
Português
Türkçe
한국어
العربية
Abstract:The markets gave back most of their earlier gains after U.S. Senate Majority Leader Mitch McConnell commented on election night “irregularities”.
The benchmark S&P 500 Index and the blue chip Dow Jones Industrial Average surged early in the session but finished off their record highs on Monday as investors speculated that a full economic reopening was finally in sight after a well-known pharmaceutical firm announced the first positive results from a late-stage COVID-19 vaccine trial.
In the cash market on Monday, the S&P 500 Index settled at 3550.50, up 41.06 or +1.22%. The Dow Jones Industrial Average closed at 29157.97, up 834.57 or +3.04% and the technology-driven NASDAQ Composite finished at 11713.78, down 181.45 or -1.63%.
[fx-dianomivideo-ad]
The markets were also supported on the opening as investors were reassured by Saturday‘s news that Joe Biden had garnered enough votes to win the U.S. presidential election. However, late in the session, the markets gave back most of their earlier gains after U.S. Senate Majority Leader Mitch McConnell on Monday said President Donald Trump was completely within his rights to look into “irregularities” from last week’s election.
Impressive Vaccine Results
Pfizer and its German partner BioNTech said a large-scale trial of their vaccine showed it was more than 90% effective in preventing COVID-19. While their vaccine study is still ongoing and requires approval, Pfizer and BioNTech said they had found no serious safety concerns so far and expected to seek U.S. emergency use authorization later this month.
The news doesnt mean the U.S. is out of the woods with the coronavirus, but if Pfizer gets approval to begin administering the vaccine, it would remove the worst case scenario – meaning the country would avoid a national lockdown. Additionally, the market is forward looking so investors are pricing in better times in the first and second quarter of next year.
[fx-article-ad]Stocks Whacked by Lockdowns Post Solid Gains
With investors already looking forward to improved earnings results next year, sectors such as energy, travel and financials which were among the hardest hit by lockdowns aimed at curbing the virus were some of the biggest percentage gainers on Monday.
Tech Giants Tumble
While cyclical stocks led the market advance on Monday, the tech-heavy NASDAQ dropped as investors dumped some of the popular stay-at-home plays such as Zoom Video and Netflix. The index finished Mondays session near its session low.
Stocks in the News
The vaccine news sent travel stocks soaring as the recovery of these companies depends on a successful economic reopening. American Airlines, Delta and United all jumped more than 15%, while Carnival, Norwegian and Royal Caribbean surged more than 25% each.
U.S. banks including Citigroup Inc and Bank of America Corp, often seen as a proxy for the broader economy, jumped about 9% each, while oil majors Exxon Mobil Corp and Chevron Corp climbed about 10%.
Losers included Netflix Inc, Amazon.com Inc and gaming company Activision Blizzard Inc fell between 1.5% and 4.7%.
Among other movers, McDonalds Corp gained about 1.0% after it beat third-quarter revenue and profit estimates, as U.S. customers ordered more hamburgers and fries in drive-through outlets and on delivery apps.
The Internals
On U.S. exchanges, 17.2 million shares changed hands in the markets busiest trading session since June and compared with the 9.68 billion average for the last 20 sessions.
Advancing issues outnumbered declining ones on the NYSE by a 3.22-to-1 ratio; on NASDAQ, a 1.96-to-1 ratio favored advancers.
The S&P 500 posted 140 new 52-week highs and 1 new low; the NASDAQ Composite recorded 246 new highs and 25 new lows, according to Reuters.
For a look at all of todays economic events, check out our economic calendar.
Disclaimer:
The views in this article only represent the author's personal views, and do not constitute investment advice on this platform. This platform does not guarantee the accuracy, completeness and timeliness of the information in the article, and will not be liable for any loss caused by the use of or reliance on the information in the article.